Enumeral Biomedical Holdings has appointed Robert Van Nostrand to its board of directors.

Van Nostrand is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including as chief compliance officer, chief financial officer and chief accounting officer.

Most recently, Van Nostrand held senior executive positions with AGI Dermatics and Aureon BioSciences. Previously, during his tenure with OSI Pharmaceuticals, he had financial responsibility for all of its significant operations and was instrumental in development of strategy, budgeting and forecasting, negotiation and closing of several major corporate collaborations, and SEC reporting.